Pharmacokinetic-pharmacodynamic modelling of tiagabine CNS effects upon chronic treatment in rats: Lack of change in concentration-EEG effect relationship

European Journal of Pharmaceutical Sciences

Volumn 12, Issue 2, 2000, Pages 141-150

  Cleton, A ^a   Altorf, B A ^a   Voskuyl, R A ^b,c   Danhof, M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adaptation; Chronic treatment; GABA uptake inhibitor; GABA uptake transporter; Pharmacodynamics; Pharmacokinetics; Tiagabine

Indexed keywords

TIAGABINE;

ADAPTATION; ANIMAL EXPERIMENT; ARTICLE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; DRUG BLOOD LEVEL; ELECTROENCEPHALOGRAM; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICONVULSANTS; BETA RHYTHM; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; GAMMA-AMINOBUTYRIC ACID; KINETICS; MALE; MODELS, THEORETICAL; NIPECOTIC ACIDS; PLACEBOS; RATS; RATS, WISTAR; REGRESSION ANALYSIS;

EID: 0033721840     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(00)00179-2     Document Type: Article

References (30)

1. Imidazenil, a partial positive allosteric modulator of GABA(A) receptors, exhibits low tolerance and dependence liabilities in the rat
2. (R)-N-[4,4-Bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain γ-aminobutyric acid uptake carrier
3. Stereoselective central nervous system effects of the R- and S-isomers of the GABA uptake blocker N-(4,4-di-(3-methylthien-2-yl)but-3-enyl) nipecotic acid in the rat
4. Mechanism-based modelling of adaptive changes in the pharmacodynamics of midazolam in the kindling model of epilepsy
5. Effect of amygdala kindling on the central nervous system effects of tiagabine: EEG effects versus GABA levels
6. Application of a combined 'effect compartment/indirect response model' to the central nervous system effects of tiagabine in the rat
7. Mechanism-based modelling of the adaptive changes in the pharmacodynamics of midazolam upon chronic treatment
8. From GABA(A) receptor diversity emerges a unified vision of GABAergic inhibition
9. Amino acids: chemistry, biology and medicine
10. The γ-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats
11. 3H] GABA into rat brain synaptosomes
12. Non-compartmental analysis based on statistical moment theory
13. High performance liquid chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection
14. Tolerance to the anticonvulsant effects of benzodiazepines
15. The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs
16. Biochemical and behaviour studies following subchronic administration of GABA uptake inhibitors in mice
17. GABA synaptic mechanisms: Stereochemical and conformational requirements
18. GABA mimetics in animal models of seizure states
19. EEG effect measures and relationships between pharmacokinetics and pharmacodynamics of psychotropic drugs
20. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of benzodiazepines: correlation with receptor binding and anticonvulsant activity
21. Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship
22. In vivo characterization of the pharmacodynamic interaction of benzodiazepine agonist and antagonist: midazolam and flunazenil
23. 6-cyclopentyladenosine in the rat
24. Anticonvulsant tolerance and withdrawal characteristics of benzodiazepine receptor ligands in different seizure models in mice. Comparison of diazepam, bretazenil and abecarnil
25. Estimating impossible curves using NONMEM
26. - ion channels modulated by multiple drug-binding sites
27. The γ-aminobutyric acid uptake inhibitor, tiagabine, is anticonvulsant in two animal models of reflex epilepsy
28. Lack of tolerance to the anticonvulsant effects of tiagabine following chronic (21 days) treatment
29. 3H]tiagabine binding to sections from mice brain
30. Semi-parametric approach to pharmacokinetic-pharmacodynamic data